Caio César Silva de Castro

Caio César Silva de Castro

Auto-generated profile, based on publicly available information

Caio César Silva de Castro

Escola de Medicina, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
HMHelena Zenedin Marchioro
Helena Zenedin Marchioro
CCCaio César Silva de Castro
Caio César Silva de Castro
VFVinicius Medeiros Fava
Vinicius Medeiros Fava
PSPaula Hitomi Sakiyama
Paula Hitomi Sakiyama
GDGerson Dellatorre
Gerson Dellatorre
HMHelio Miot
Helio Miot
Vitiligo is a complex disease whose pathogenesis results from the interaction of genetic components, metabolic factors linked to cellular oxidative stress, melanocyte adhesion to the epithelium, and immunity (innate and adaptive), which culminate in aggression against melanocytes. In vitiligo, melanocytes are more sensitive to oxidative damage, leading to the increased expression of proinflammatory proteins such as HSP70. The lower expression of epithelial adhesion molecules, such as DDR1 and E-cadherin, facilitates damage to melanocytes and exposure of antigens that favor autoimmunity. Activation of the type 1-IFN pathway perpetuates the direct action of CD8+ cells against melanocytes, facilitated by regulatory T-cell dysfunction. The identification of several genes involved in these processes sets the stage for disease development and maintenance. However, the relationship of vitiligo with environmental factors, psychological stress, comorbidities, and the elements that define individual susceptibility to the disease are a challenge to the integration of theories related to its pathogenesis.

23 May 2023 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
HMHelio Miot
Helio Miot
PCPaulo Criado
Paulo Criado
CCCaio César Silva de Castro
Caio César Silva de Castro
MIMayra Ianhez
Mayra Ianhez
CTCarolina Talhari
Carolina Talhari
PRPaulo Müller Ramos
Paulo Müller Ramos
The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.

12 August 2024 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PCPaulo Criado
Paulo Criado
HMHelio Miot
Helio Miot
RBRoberto Bueno-Filho
Roberto Bueno-Filho
MIMayra Ianhez
Mayra Ianhez
RCRoberta Fachini Jardim Criado
Roberta Fachini Jardim Criado
CCCaio César Silva de Castro
Caio César Silva de Castro
Atopic dermatitis is a chronic, recurrent, and multifactorial skin-mucosal manifestation resulting from the interaction between elements mainly associated with the skin barrier deficit, the homeostasis of the immune response, neurological aspects, and patterns of reactivity to environmental antigens, which are established in genetically predisposed individuals. In addition to the skin, atopic diathesis involves other organs such as the airways (upper and lower), eyes, digestive tract, and neuropsychiatric aspects, which inflict additional morbidity on the dermatological patient. The different phenotypes of the disease fundamentally depend on the participation of each of these factors, in different life circumstances, such as age groups, occupational exposure patterns, physical activity, pollution, genetic load, and climatic factors. A better understanding of the complexity of its pathogenesis allows not only the understanding of therapeutic targets but also how to identify preponderant elements that mediate disease activity in each circumstance, for selecting the best treatment strategies and mitigation of triggering factors. This narrative review presents an update on the pathogenesis of atopic dermatitis, especially aimed at understanding the clinical manifestations, the main disease phenotypes and the context of available therapeutic strategies.

1 September 2014 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
AFAdriane Reichert Faria
Adriane Reichert Faria
RTRoberto Gomes Tarlé
Roberto Gomes Tarlé
GDGerson Dellatorre
Gerson Dellatorre
MMMarcelo Távora Mira
Marcelo Távora Mira
CCCaio Cesar Silva de Castro
Caio Cesar Silva de Castro
In an unprecedented effort in the field of vitiligo, a global consensus resulted on a suggested new classification protocol for the disease. The main histopathological finding in vitiligo is the total absence of functioning melanocytes in the lesions, while the inflammatory cells most commonly found on the edges of the lesions are CD4+ and CD8+ T lymphocytes. Physical and pharmacological treatment strategies aim to control the autoimmune damage and stimulate melanocyte migration from the unaffected edges of lesions and the outer hair follicle root sheath to the affected skin; moreover, surgical treatments can be combined with topical and physical treatments.

1 June 2014 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
RTRoberto Gomes Tarlé
Roberto Gomes Tarlé
LNLiliane Machado Do Nascimento
Liliane Machado Do Nascimento
MMMarcelo Távora Mira
Marcelo Távora Mira
CCCaio Cesar Silva de Castro
Caio Cesar Silva de Castro
Vitiligo is a chronic stigmatizing disease, already known for millennia, which mainly affects melanocytes from epidermis basal layer, leading to the development of hypochromic and achromic patches. Its estimated prevalence is 0.5% worldwide. The involvement of genetic factors controlling susceptibility to vitiligo has been studied over the last decades, and results of previous studies present vitiligo as a complex, multifactorial and polygenic disease. In this context, a few genes, including DDR1, XBP1 and NLRP1 have been consistently and functionally associated with the disease. Notwithstanding, environmental factors that precipitate or maintain the disease are yet to be described. The pathogenesis of vitiligo has not been totally clarified until now and many theories have been proposed. Of these, the autoimmune hypothesis is now the most cited and studied among experts. Dysfunction in metabolic pathways, which could lead to production of toxic metabolites causing damage to melanocytes, has also been investigated. Melanocytes adhesion deficit in patients with vitiligo is mainly speculated by the appearance of Köebner phenomenon, recently, new genes and proteins involved in this deficit have been found.

1 November 2020 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
GDGerson Dellatorre
Gerson Dellatorre
DADaniela Alves Pereira Antelo
Daniela Alves Pereira Antelo
RBRoberta Buense Bedrikow
Roberta Buense Bedrikow
TCTania Ferreira Cestari
Tania Ferreira Cestari
IFIvonise Follador
Ivonise Follador
CCCaio Cesar Silva de Castro
Caio Cesar Silva de Castro
Vitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written. The objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence. Seven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. The experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.